Showing 10 posts of 100 posts found.

Novartis’ Signifor recommended in Europe

January 20, 2012
Research and Development, Sales and Marketing CHMP, Cushing's disease, Novartis, Signifor

A European committee has recommended Novartis’ Signifor for the treatment of a rare, debilitating endocrine disorder. The European Committee for …

Gilenya image

EMA to review safety of MS drug Gilenya

January 20, 2012
Research and Development, Sales and Marketing CHMP, EMA, Novartis, gilenya

The European Medicines Agency has begun a review into the safety of Novartis’ multiple sclerosis drug Gilenya. This follows concerns …

AstraZeneca’s thyroid cancer drug gets CHMP nod

November 21, 2011
Sales and Marketing AstraZeneca, CHMP, Caprelsa, vandetanib

AstraZeneca’s thyroid cancer pill Caprelsa has taken a step closer to European approval after being recommended by the CHMP.Caprelsa (vandetanib) …

CHMP roundup

May 24, 2011
Sales and Marketing CHMP, EMA, Fampyra, Vibativ, Victrelis, Xgeva, Yervoy

The latest products to be recommended for European approval include MSD’s Victrelis, Astellas Pharma Europe’s Vibativ, Amgen Europe’s Xgeva and …

European recommendation for GSK’s lupus drug Benlysta

May 23, 2011
Sales and Marketing Benlysta, CHMP, GlaxoSmithKline, Lupus

GlaxoSmithKline’s first-in-class lupus drug Benlysta has been given a major boost by regulators in the European Union. The European Medicines …

Boehringer Ingelheim

Boehringer’s Pradaxa recommended for expanded European licence

April 18, 2011
Sales and Marketing Boehringer Ingelheim, CHMP, Pradaxa

Pradaxa is on course to expand its European licence with a recommendation from the CHMP for a new indication in …

Roche's Avastin (bevacizumab)

Avastin’s breast cancer use to continue in Europe

March 2, 2011
Sales and Marketing CHMP, Cancer, European Commission, Roche, avastin, bevacizumab, breast cancer, docetaxel, paclitaxel

Roche’s Avastin will remain on the market as a treatment for breast cancer, but only in combination with paclitaxel, the …

Novartis’ Lucentis recommended for wider EU licence

October 25, 2010
Sales and Marketing CHMP, Genentech, Lucentis, Novartis, diabetic macular edema, ranibizumab

Novartis’ Lucentis has been recommended for approval in Europe to treat people suffering from vison loss due to diabetes. The …

Merck will appeal EMA’s Movectro decision

October 12, 2010
Sales and Marketing CHMP, EMA, Merck KGaA, Merck Serono, Movectro

Merck KGaA is poised to appeal the EMA’s decision on its MS treatment Movectro after the regulator rejected the drug …

European green light for Allergan’s Ozurdex

May 25, 2010
Sales and Marketing Allergan, CHMP, Ozurdex, macular oedema

European authorities have given the green light for Ozurdex, a treatment for adults with a potentially serious eye disease. Ozurdex …

Latest content